好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (9:00 AM-5:00 PM)
407

The aim of this study was to determine structural brain abnormalities in patients with adult-onset myotonic dystrophy type 1 (DM1) and correlate them to clinical and neuropsychological measures.

DM1 is a dominantly inherited repeat expansion disorder with variable clinical phenotype and central nervous system involvement. Prior neuroimaging studies in DM1 have identified widespread morphological abnormalities including global atrophy, ventriculomegaly and white matter hyperintensities.

Structural T1 weighted images were collected in 36 DM1 patients and 36 age and gender matched controls. Image preprocessing and voxel-based morphometry analysis were conducted using the Computational Anatomy Toolbox (CAT12). Global and regional gray (GM) and white matter (WM) volume differences were assessed through group comparisons and linear regression analysis with clinical and neuropsychological measures.

Compared to healthy controls, DM1 patients had widespread global and regional GM and WM volume reductions that were correlated with disease severity. An enlargement of mesial temporal structures including parahippocampal gyrus, fusiform gyrus, uncus, entorhinal cortex, hippocampus and amygdala was noted in DM1. GM volume loss in right inferior parietal lobule/angular gyrus and WM volume loss in left middle temporal gyrus were correlated with excessive daytime sleepiness in DM1. Volume loss in lentiform nucleus was inversely correlated with motor speed in DM1. 

In this study, we describe an abnormal enlargement of mesial temporal structures in the setting of widespread GM and WM volume loss in DM1 patients. GM and WM volume loss were associated with disease severity in DM1. Specific regional patterns of volume loss were associated with excessive daytime sleepiness and motor speed abnormalities in DM1. The mesial temporal enlargement could be compensatory or pathological and may underlie apathy and impaired social and emotional cognition and functioning noted in DM1. It is also possible that these changes represent chronic effects of sleep disordered breathing that are prevalent in DM1.

Authors/Disclosures
Faisal Fecto, MD, PhD (Advocate Medical Group)
PRESENTER
The institution of Dr. Fecto has received research support from NINDS.
No disclosure on file
Jacinda B. Sampson, MD, PhD Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viking Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sampson has received research support from Marigold Foundation. Dr. Sampson has a non-compensated relationship as a Scientific Advisory Committee with Myotonic Dystrophy Foundation that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
John W. Day, MD, PhD (Stanford University School of Medicine) Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapy. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PepGen. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Epirium Bio. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biosciences. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Muscular Dystrophy Association. The institution of Dr. Day has received research support from Astellas Pharma. The institution of Dr. Day has received research support from Novartis Gene Therapy. The institution of Dr. Day has received research support from Biogen. The institution of Dr. Day has received research support from Roche/Genentech. The institution of Dr. Day has received research support from Sanofi/Genzyme. The institution of Dr. Day has received research support from Sarepta. The institution of Dr. Day has received research support from Scholar Rock. The institution of Dr. Day has received research support from AMO Pharma. The institution of Dr. Day has received research support from AnnJi. Dr. Day has received research support from CureSMA. The institution of Dr. Day has received research support from Muscular Dystrophy Association. The institution of Dr. Day has received research support from Ionis Pharmaceuticals. The institution of Dr. Day has received research support from NMD Pharma. The institution of Dr. Day has received research support from SMA Foundation. Dr. Day has received intellectual property interests from a discovery or technology relating to health care.